These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26783469)

  • 1. Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis.
    Rochau U; Kluibenschaedl M; Stenehjem D; Kuan-Ling K; Radich J; Oderda G; Brixner D; Siebert U
    Leuk Res Treatment; 2015; 2015():982395. PubMed ID: 26783469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
    Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting.
    Muresan B; Mamolo C; Cappelleri JC; Postma MJ; Heeg B
    Appl Health Econ Health Policy; 2021 Nov; 19(6):929-940. PubMed ID: 34250585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation.
    Yamamoto C; Nakashima H; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Mashima K; Nagayama T; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Sugimoto M; Ishihara Y; Ashizawa M; Hatano K; Sato K; Oh I; Fujiwara SI; Ueda M; Ohmine K; Muroi K; Kanda Y
    Blood Adv; 2019 Nov; 3(21):3266-3277. PubMed ID: 31698458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.
    Hirt C; Iannazzo S; Chiroli S; McGarry LJ; le Coutre P; Stenke L; Dahlén T; Lipton JH
    Appl Health Econ Health Policy; 2019 Aug; 17(4):555-567. PubMed ID: 31168745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.
    Yue X; Hincapie AL; Li Y; Guo JJ
    Leuk Lymphoma; 2022 Apr; 63(4):946-954. PubMed ID: 34775888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy.
    Bonifacio M; Maheshwari V; Tran D; Agostoni G; Filioussi K; Viana R
    Pharmacoecon Open; 2022 Jan; 6(1):95-104. PubMed ID: 34297312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
    Breitscheidel L
    J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Hamilton J; Stevens J; Rowntree C; Martyn-St James M; Rawdin A; Wong R
    Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia.
    Conti RM; Padula WV; Becker RV; Salamone S
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1077-1085. PubMed ID: 34337991
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical decision analysis for first-line therapy of chronic myeloid leukemia.
    Rochau U; Sroczynski G; Wolf D; Schmidt S; Conrads-Frank A; Jahn B; Saverno K; Brixner D; Radich J; Gastl G; Siebert U
    Leuk Lymphoma; 2014 Aug; 55(8):1758-67. PubMed ID: 24160847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pandor A; Stevenson M; Stevens J; James MM; Hamilton J; Byrne J; Rudin C; Rawdin A; Wong R
    Pharmacoeconomics; 2018 Aug; 36(8):903-915. PubMed ID: 29480454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations.
    Haznedaroglu IC
    Expert Opin Pharmacother; 2013 Oct; 14(15):2005-10. PubMed ID: 23984805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
    Khoury HJ; Bixby DL
    Leuk Lymphoma; 2015 Mar; 56(3):568-76. PubMed ID: 24884315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review.
    Morozova EV; Vlasova YY; Pryanishnikova MV; Lepik KV; Afanasyev BV
    Biomark Insights; 2015; 10(Suppl 3):43-7. PubMed ID: 26673003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.